Rigel Pharmaceuticals (RIGL) Net Income towards Common Stockholders (QoQ) (2010 - 2026)
Rigel Pharmaceuticals (RIGL) Net Income towards Common Stockholders (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Rigel Pharmaceuticals | 696.99 Mn | 550.30 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.77% |
| Dec 31, 2025 | 860.81% |
| Sep 30, 2025 | -53.20% |
| Jun 30, 2025 | 420.82% |
| Mar 31, 2025 | -20.19% |
| Dec 31, 2024 | 15.46% |
| Sep 30, 2024 | 1,305.92% |
| Jun 30, 2024 | 87.51% |
| Mar 31, 2024 | -75,072.73% |
| Dec 31, 2023 | 100.19% |
| Sep 30, 2023 | 13.76% |
| Jun 30, 2023 | 51.24% |
| Mar 31, 2023 | -1,066.17% |
| Dec 31, 2022 | 107.36% |
| Sep 30, 2022 | -41.10% |
| Jun 30, 2022 | 50.84% |
| Mar 31, 2022 | -21.41% |
| Dec 31, 2021 | -7.89% |
| Sep 30, 2021 | -51.60% |
| Jun 30, 2021 | -134.99% |